1. Tratamiento De La Tuberculosis Dr. J.Javier Díaz Castañón Hospital Dr. Angel Leaño Universidad Autonoma de Guadalajara

18. Issues relating to the use of BCG in immunization Programmes DEPARTMENT OF VACCINES AND BIOLOGICALS World Health Organization Geneva 1999 www.who.int/vaccines-documents/DocsPDF99/www9943.pdf

35. Tuberculosis TAES

44. MDR Tuberculosis San Francisco Experience -Costs Case Drug HIV Costs(US DLLS) Resist. Status Outcome Inpatient Outpatient Total 1 4 Neg Cured 20,580 20,580 2 6 Pos Died 21,560 31,920 53,480 3 3 Neg Cured 27,752 27,752 4 5 Neg Cured 154,107 154,107 5 3 Neg Cured 15,765 15,765 6 2 Pos Died 13,720 24,775 38,495 7 2 Neg Cured 21,929 21,929 8 3 Neg Cured 17,192 17,192 9 3 Neg Cured 21,654 21,654 10 2 Pos Died 29,400 13,654 43,054 11 5 Pos Died 30,380 55,290 85,670 Total 95,060 404,921 499,981 Mean 23,765 36,811 45,452 Median 25, 480 21, 957 24,775

45. CONCEPTOS BASICOS EN RETRATAMIENTOS El Mejor Retratamiento debe Desarrollarse Varios Años antes, con la Instauración de un Buen Tratamiento Inicial 2 HRZE / 4 H 3 R 3

46. Quimioterapia de la TB Pautas Recomendadas EN CASOS INCIDENTES Tratamiento Enfermos Iniciales 2 HRZE / 4 H 3 R 3 Retratamiento Estándar Fármacos 1ª Línea 2 HRZES / 1 HRZE / 5H 3 R 3 E 3 Retratam Estándar 2ª Línea 6Z-Cx-Prt-Kn / 15 Z-Cx-Prt Ret. Individ. 2ª Línea